MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will be participating at the following investor conferences next week:

BTIG Biotechnology Conference 2022

Date: Monday, August 8, 2022

Location: Hybrid Event at St. Regis Hotel, New York, New York

Chief Financial Officer Michael Kaseta will also participate in a live Fireside Chat at 2:00 p.m. To listen to the event, please contact your BTIG representative with interest.

Wedbush PacGrow 2022 Healthcare Conference

Date: Tuesday, August 9, 2022

Location: Virtual Event

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information for Media & Investors

Jason Adair

Senior Vice President, Corporate Development and Strategy

919.328.4400

jason.adair@liquidia.com